首页> 中国专利> 抗绵羊包虫病感染的基因rEg.P29分子工程疫苗及其制备方法和应用

抗绵羊包虫病感染的基因rEg.P29分子工程疫苗及其制备方法和应用

页面导航

摘要
著录项
法律信息
相似文献

摘要

一种抗绵羊包虫病感染的基因工程疫苗，是从细粒棘球蚴中国株提取RNA并通过RT-PCR获得Eg.P29基因分子，再构建P29/pET28a原核表达载体，在大肠杆菌BL21中IPTG诱导表达重组的蛋白rEg.P29疫苗，其保藏号为：CCTCC？M2015425。本发明的细粒棘球蚴重组疫苗在绵羊身上进行免疫保护验证，免疫保护力也达到了94.8％。该疫苗候选分子将有望应用于制备抗绵羊包虫病感染的疫苗，在肝包虫防治中发挥着巨大的作用。

著录项

公开/公告号CN105343873A

专利类型发明专利
公开/公告日2016-02-24

原文格式PDF
申请/专利权人宁夏医科大学;
展开▼

申请/专利号CN201510703704.X
发明设计人赵巍;
展开▼

申请日2015-10-27
分类号A61K39/00;A61K48/00;A61P33/10;C12N15/12;C12N15/70;
代理机构宁夏专利服务中心;
代理人冯艳清
地址 750004 宁夏回族自治区银川市兴庆区胜利街1160号
入库时间 2023-12-18 14:16:33

法律信息

法律状态公告日

法律状态信息

法律状态
2019-03-05

发明专利申请公布后的视为撤回 IPC(主分类):A61K39/00 申请公布日:20160224 申请日:20151027

发明专利申请公布后的视为撤回
2016-03-23

实质审查的生效 IPC(主分类):A61K39/00 申请日:20151027

实质审查的生效
2016-02-24

公开

公开

相似文献

专利
中文文献
外文文献

1. 抗绵羊包虫病感染的基因rEg.P29分子工程疫苗及其制备方法和应用 [P] . 中国专利： CN105343873A . 2016-02-24
2. 抗绵羊包虫病感染的基因rEg.myophilin分子工程疫苗、其制备方法及应用 [P] . 中国专利： CN105343872A . 2016-02-24
3. Nucleic acid molecule, recombinant vector, polypeptide, eukaryotic amino acid racemase, antibodies, host cell, methods to produce polypeptide, to detect a parasite and a eukaryotic protein, to screen active molecules, to detect and quantify the presence or absence of a sequence, to inhibit a eukaryotic protein, to produce a eukaryotic and d-aminoacid recombinant amino acid racemase and to prevent or inhibit infection, plasmid, immune complex, kit to detect a parasite, fragment of a polynucleotide, eukaryotic protein, processes to prepare a purified eukaryotic protein, to detect an infection and for infection and to screen a molecule, immunizing composition, vaccine composition, any molecular modification of the gene or a fragment of the gene, use of any molecular or biochemical modification of the enzymatic activity of the racemase, and , any molecule or composition to [P] . BR0016129A . 2002-08-20

机译：核酸分子，重组载体，多肽，真核氨基酸消旋酶，抗体，宿主细胞，生产多肽，检测寄生虫和真核蛋白质，筛选活性分子，检测和定量序列存在或不存在的方法，抑制真核蛋白，产生真核和d-氨基酸重组氨基酸消旋酶并预防或抑制感染，质粒，免疫复合物，检测寄生虫，多核苷酸片段，真核蛋白的试剂盒，制备纯化的真核生物的方法蛋白质，以检测感染和感染，并筛选分子，免疫组合物，疫苗组合物，基因或基因片段的任何分子修饰，消旋酶酶活性的任何分子或生化修饰，以及，任何分子或组成
4. Process of preparation of an antigen derived from a microorganism that causes infectious and / or parasitic disease Process of preparation of an antigen from T cruzi antigen derived from a microorganism that causes infectious disease and / or parasitic antigen derived from T cruzi that causes Chagas disease composition the base of an antigen derived from microorganism that causes infectious and / or parasitic disease composition the base of antigen from T cruzi use of the antigen derived from microorganism that causes infectious and / or parasitic disease in serological tests and vaccines use of antigen derived from T cruzi cause of chagas disease in serological tests and vaccines process for detecting antibodies against microorganism antigen causing infectious and / or parasitic disease and confirmatory serodiagnosis kit for infectious and / or parasitic disease [P] . BR9503451A . 1997-09-30

机译：源自引起传染性和/或寄生虫病的微生物的抗原的制备过程由源自引起传染性疾病的微生物的T克鲁兹抗原的抗原和/或引起恰加斯病组合物的源自T cruzi的寄生虫抗原的制备过程源自引起感染和/或寄生虫病的微生物的抗原的成分组成来自T cruzi的抗原的碱基在血清学测试和疫苗中使用源自引起感染和/或寄生虫病的微生物的抗原的用途血清学测试和疫苗过程中查加斯病的克鲁斯病因，用于检测针对引起传染病和/或寄生虫病的微生物抗原的抗体，以及传染病和/或寄生虫病的确诊血清诊断试剂盒
5. Genetically engineered hepatitis c virus (hcv) nucleic acid clone, plasmid clone that houses a life-size hcv cdna, dna or rna transcribed from the full-length hcv cdna, transfected and in vitro infected host cell line with hcv, non-human animal infected with hcv, hcv viral particle, in vitro test system, hcv cell free, hcv vaccine and hcv test set and processes for identifying a cell line that is permissive and an animal that is permissive for hcv infection, to select hcv with adaptive mutations that allow higher levels of hcv replication in a permissive cell line, to infect an animal with hcv, to spread hcv in vitro, to transduce an animal susceptible to hcv infection with a heterologous gene, to produce hcv viral particles, hcv particle proteins and hcv antibodies, to separate agents capable of to modulate hcv replication, to prepare a hcv nucleic acid and to detect hcv antibodies in a biological sample from a patient. [P] . BR9808147A . 2000-03-28

机译：基因工程丙型肝炎病毒（hcv）核酸克隆，质粒克隆，其中包含从全长hcv cdna转录而来的真人大小的hcv cdna，dna或rna，并通过非人类动物的hcv转染和体外感染宿主细胞系被hcv感染，hcv病毒颗粒，体外测试系统，无hcv细胞，hcv疫苗和hcv测试仪的感染以及鉴定允许的细胞系和允许感染hvv的动物的过程，以选择具有以下适应性突变的hcv：允许在允许的细胞系中进行更高水平的hvv复制，以hvv感染动物，在体外传播hvv，用异源基因转导易感染hvv的动物，产生hvv病毒颗粒，hvv颗粒蛋白和hvv抗体分离能够调节hcv复制的试剂，制备hcv核酸并检测患者生物样品中的hcv抗体。